Are clinical characteristics of familial benign prostatic hyperplasia different than in sporadic cases?

Urol Int. 2002;68(3):178-82. doi: 10.1159/000048446.

Abstract

Objective: Familial benign prostatic hyperplasia (BPH) is a recently popularized entity with yet uncertain clinical and pathological features. In the present study we investigated whether there was any difference between clinical characteristics of familial and sporadic BPH in a series of 148 surgically treated BPH patients.

Materials and methods: A retrospective analysis was performed in 148 patients subjected to transvesical or transurethral prostatectomy to determine the clinical features of familial BPH. Patients were categorised as having familial BPH when 3 or more (including the patient) first-degree family members gave a history of BPH. Accordingly 23 cases who fit this criterion were accepted as having familial BPH and the rest of the cases were taken as the control group. The two groups were compared with respect to age, International Prostate Symptom Score (IPSS), quality of life score, prostate specific antigen (PSA), maximum urinary flow rate and the weight of the surgical prostate specimen.

Results: The mean age, IPSS, quality of life score, total PSA, maximum urinary flow rate and the weight of the surgical prostate specimen were found as 65.13 +/- 5.51 years, 23.13 +/- 4.82, 4.78 +/- 0.95, 6.0 +/- 4.1 ng/ml, 6.9 +/- 2.7 ml/s and 62.96 +/- 38.76 g, respectively, in the familial BPH group whereas the same parameters were measured as 68.13 +/- 7.68 years, 24.74 +/- 3.73, 4.52 +/- 0.85, 5.93 +/- 4.75 ng/ml, 4.6 +/- 1.71 ml/s and 70.87 +/- 53.21 g, respectively. No significant difference was present between familial and sporadic BPH cases in any of the studied parameters.

Conclusion: The clinical features of familial BPH did not differ significantly from those of sporadic BPH.

MeSH terms

  • Aged
  • Diagnosis, Differential
  • Humans
  • Male
  • Prostate-Specific Antigen / blood
  • Prostatic Hyperplasia / diagnosis*
  • Prostatic Hyperplasia / genetics*
  • Prostatic Hyperplasia / surgery
  • Quality of Life
  • Retrospective Studies
  • Transurethral Resection of Prostate

Substances

  • Prostate-Specific Antigen